PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Studies Support Changing Perspectives Of Glass Vial Performance Characteristics

The global market for glass pharmaceutical containers is projected to exceed $10.5 billion within the next three years, solidifying glass as arguably the most widely used primary packaging material for injectable drug products.

In pharma manufacturing, the performance of the primary packaging is critical to ensuring drug product stability, safety and efficacy. Pharmaceutical grade glass vials are widely used for parenteral therapies, however, not all glass vials offer the same performance, especially for small volume parenterals, or SVPs, which are defined as <= 100mL. A primary distinction is whether a vial is made by converting previously produced glass tubing, or whether it is moulded directly from the glass furnace.

SVP Vials

Tubular vials are produced in two separate consecutive manufacturing operations. First, a glass tube with the desired outer diameter (OD) and internal diameter (ID) is drawn from a glass furnace, hardened, and cut into lengths of approximately two metres. Then in a separate operation, usually in a different factory, these tubes are converted into vials by heating and forming the vial opening (known as the finish), the vial shoulder, and then the vial heel, before remelting the glass to close the bottom of the vial. For tubular vials, this remelting process can alter the glass composition in specific areas, particularly at the bottom and heel. Tubular vials are well known for their high optical quality and uniform wall thicknesses, most commonly in the 0.8–1.2 mm range.

In contrast, moulded vials are formed in a single melting process. Molten glass exits the furnace with the consistency of thick honey, but at temperatures exceeding 1,500⁰C. The molten glass flows through a round orifice where the stream is cut into individual “glass gobs”, each equal to the weight of the vial it will form. These gobs are guided by gravity into a two-stage moulding process where the vial takes shape. The glass transitions from a molten state at over 1,000°C to a fully formed vial at around 600°C in under ten seconds. Since moulded vials are not remelted, they exhibit exceptionally high interior surface homogeneity. Moulded vial wall thicknesses are almost always greater than 1 mm, and typically ranging from 1.2–1.8 mm, and they are renowned for strength and lower susceptibility to breakage.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026